Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Very Bullish +85

Why Moderna (MRNA) Stock Is Trading Up Today - TradingView

📈 Moderna shares jumped 17.4% after settling a patent dispute with Arbutus Biopharma and Genevant Sciences for up to $2.25 billion.

⚖️ The settlement removes future royalty obligations for Moderna's entire infectious disease portfolio, eliminating legal uncertainty.

🏥 EMA issued a positive opinion on Moderna's combination vaccine for flu and COVID-19 in adults aged 50 and older.

💊 FDA accepted an amended application for the mRNA-1010 seasonal flu vaccine targeting ages 50+ with a target decision of August 5, 2026.

📉 Moderna shares are highly volatile, having recorded 50 moves greater than 5% over the last year.

🚀 Stock reached a new 52-week high of $57.93 and is up 87.7% since the beginning of the year.

Bullish Signals
  • The settlement of the patent dispute removes a major legal and financial uncertainty that had negatively impacted the company's stock valuation.
  • Moderna will not owe future royalties on its infectious disease portfolio, improving long-term profitability prospects.
  • A positive opinion from the European Medicines Agency validates the efficacy and safety of the combination vaccine for influenza and COVID-19 in older adults.
  • The FDA accepted an amended application for the new seasonal flu vaccine, removing a significant regulatory hurdle for the 2026-2027 flu season.
  • Moderna has achieved a new 52-week high of $57.93, reflecting strong investor confidence in its recent developments.
Full Analysis
Moderna (MRNA) shares surged 17.4% in the afternoon session after the company settled a long-running patent dispute with Arbutus Biopharma and Genevant Sciences. The agreement, valued at up to $2.25 billion, resolves legal uncertainties surrounding the technology used in its COVID-19 vaccine and eliminates future royalty obligations for Moderna's entire infectious disease portfolio. In addition to the settlement, Moderna received a positive opinion from the European Medicines Agency regarding its combination vaccine for influenza and COVID-19 in individuals aged 50 and older. This regulatory milestone provides clarity for the company's product pipeline and removes significant financial and legal headwinds that had previously weighed on investor sentiment. The stock closed at $57.86, up 16.1% from the previous close, marking a rare but significant move for the volatile biotechnology firm. This rally follows earlier positive news regarding the FDA's acceptance of an amended application for its new seasonal flu vaccine, mRNA-1010, which targets adults aged 50 to 64 and older.